Try our Advanced Search for more refined results

United States of America, et al., ex. rel. Charles Arnstein and Hossam Senousy v. Teva Pharmaceuticals USA, Inc., et al.

  1. January 06, 2020

    Teva To Pay $54M To End FCA Suit Alleging Bribes To Doctors

    Teva Pharmaceuticals has agreed to pony up $54 million to resolve a False Claims Act case accusing it of using speaker events to bribe doctors to prescribe two of its drugs, attorneys for two whistleblowers who brought the suit announced Monday.

  2. March 20, 2019

    Teva's 'Strategic Decision' On FCA Testimony Gets Judge's Ire

    A New York federal judge said that Teva Pharmaceuticals made a "strategic decision" not to challenge expert testimony in a False Claims Act case and that she has "no interest" in revisiting a recent ruling in light of new challenges.

  3. February 28, 2019

    Teva Can't Beat Whistleblowers' FCA Suit Over Paid Speakers

    Teva Pharmaceuticals USA Inc. must face a False Claims Act suit accusing it of using speaker events to bribe doctors to prescribe two of its drugs, as the whistleblowers sufficiently alleged that the programs were shams, a New York federal court has ruled.

  4. September 14, 2018

    Relators Slam Teva's Quick Win Bid In Overpaid Speaker Suit

    A pair of False Claims Act whistleblowers accusing Teva Pharmaceuticals USA Inc. of using speaker events to bribe doctors to prescribe two of its drugs have urged a New York federal court to deny the drugmaker a quick win in their suit.

  5. August 14, 2018

    Speaker Program Payments Weren't Kickbacks, Teva Says

    A pair of False Claims Act whistleblowers accusing Teva Pharmaceuticals USA Inc. of using speaker events to bribe doctors to prescribe two of its drugs haven't actually shown that Teva's programs involved any illegal activity, the drug company has told a New York federal court.